Expanded IFPMA Code of Practice for pharma industry goes into effect around the world

Tuesday, September 4, 2012 12:44 PM

The International Federation of Pharmaceutical Manufacturers and Associations’ (IFPMA) expanded Code of Practice has taken effect around the world. Governing how companies interact with healthcare professionals, medical institutions and patient organizations, this new code has been adopted by all IFPMA member companies and member associations.

“Advancing medical knowledge and improving global public health depend on regular information-sharing interactions between the medical community and pharmaceutical companies. These exchanges ensure patients benefit from the most up-to-date information regarding medicines,” said Eduardo Pisani, IFPMA Director General. “Ensuring that governments, healthcare providers and patients are confident that interactions with our members are conducted to the highest ethical and professional standards is our commitment.”

In March, IFPMA announced a six-month period for members to adopt the updated code. Beyond addressing interactions, the code now also includes high-level guiding principles for practice; a clear distinction between gifts, promotional aids and items of medical utility; guidance for supporting continuing medical education; and a provision on disclosure of clinical trials information. The code continues to provide guidance for filing complaints and prohibits pre-approval promotional activities for pharmaceutical products, company-sponsored entertainment at events, and providing or offering personal gifts to healthcare professionals.

IFPMA represents research-based pharmaceutical companies and associations across the globe with 1.3 million employees worldwide. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions to improve global health.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 21

As job growth in drug development sector soars, more employees are seeking new opportunities

U.K. study: Prisoners should have the right to participatein clinical trials on moral grounds, for healthcare access

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs